Insight Molecular Diagnostics (IMDX) Current Assets (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Current Assets data on file, last reported at $30.5 million in Q1 2026.

• Quarterly Current Assets fell 15.85% year-over-year to $30.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.5 million (down 15.85% YoY) and the FY2025 annual result came in at $15.3 million, up 30.16% from the prior year.
• Current Assets grew to $30.5 million in Q1 2026 per IMDX's latest filing, from $15.3 million in the prior quarter.
• The five-year high for Current Assets was $49.4 million in Q2 2022, with the low at $4.8 million in Q3 2024.
• Average Current Assets over 5 years is $21.4 million, with a median of $21.0 million recorded in 2023.
• Year-over-year, Current Assets sank 71.67% in 2024 and jumped 454.9% in 2025.
• Insight Molecular Diagnostics' Current Assets stood at $25.5 million in 2022, then tumbled by 58.11% to $10.7 million in 2023, then advanced by 9.92% to $11.8 million in 2024, then jumped by 30.16% to $15.3 million in 2025, then surged by 99.38% to $30.5 million in 2026.
• Business Quant data shows IMDX's Current Assets at $30.5 million in Q1 2026, $15.3 million in Q4 2025, and $21.4 million in Q3 2025.